The study protocol is a single-arm, open label pilot study designed to evaluate the impact of PCSK-9 inhibition on coronary blood flow in patients with stable coronary artery disease. Patients with stable coronary artery disease will be recruited from the BWH Cardiovascular Medicine clinic and/or from the BWH Nuclear Cardiology Laboratory. A target sample size of 35 participants will undergo imaging with N-13 ammonia or Rubidium-82 positron emission tomography (PET) and coronary computed tomography angiography (CCTA) before and after 12 months of PCSK-9 inhibition with Evolocumab to assess changes in myocardial blood flow, plaque volume, and vascular endothelial function.
2 Primary · 1 Secondary · Reporting Duration: Change (from baseline) in TPD, as measured by PET imaging at 52 weeks after initiation of Evolocumab therapy.
Experimental Treatment
35 Total Participants · 1 Treatment Group
Primary Treatment: Evolocumab · No Placebo Group · Phase 4
Age 50 - 90 · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: